Losartan News and Research

RSS
Losartan is a drug used to treat high blood pressure. Losartan blocks the action of chemicals that make blood vessels constrict (get narrower). It is a type of angiotensin II receptor antagonist. Also called Cozaar and losartan potassium.
Losartan may not increase risk of all-cause mortality in heart failure patients

Losartan may not increase risk of all-cause mortality in heart failure patients

Marfan syndrome researcher to receive March of Dimes/Colonel Harland Sanders Award

Marfan syndrome researcher to receive March of Dimes/Colonel Harland Sanders Award

Losartan may help prevent smoking-related COPD

Losartan may help prevent smoking-related COPD

Lostartan can reduce cigarette smoke-induced lung injury

Lostartan can reduce cigarette smoke-induced lung injury

Merck third quarter global sales increase 8% to $12.0 billion

Merck third quarter global sales increase 8% to $12.0 billion

Common genetic variant may predispose people to acute dissections

Common genetic variant may predispose people to acute dissections

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

Angiotensin receptor blockers do not increase risk of cancer: FDA

Angiotensin receptor blockers do not increase risk of cancer: FDA

Losartan therapy improves muscle injury regeneration and prevents disuse atrophy

Losartan therapy improves muscle injury regeneration and prevents disuse atrophy

Merck first quarter sales increase 1% to $11.6 billion for 2011

Merck first quarter sales increase 1% to $11.6 billion for 2011

Scientists discover new clues about mechanism behind losartan drug's protective effects

Scientists discover new clues about mechanism behind losartan drug's protective effects

Merck reports GAAP net income of $861 million for 2010

Merck reports GAAP net income of $861 million for 2010

Generic drugs to treat hypertension, heart failure could help NHS save £200 million

Generic drugs to treat hypertension, heart failure could help NHS save £200 million

Losartan improves effectiveness of nanotherapeutics against cancer

Losartan improves effectiveness of nanotherapeutics against cancer

Teva third quarter net sales increase 20% to $4.3 billion

Teva third quarter net sales increase 20% to $4.3 billion

Merck reports $342 million net income for 2010 third quarter

Merck reports $342 million net income for 2010 third quarter

Mylan granted FDA approvals for generic Hyzaar and Cozaar ANDAs

Mylan granted FDA approvals for generic Hyzaar and Cozaar ANDAs

ANDA approved for Losartan Potassium Tablets USP, Losartan Potassium and Hydrochlorothiazide Tablets

ANDA approved for Losartan Potassium Tablets USP, Losartan Potassium and Hydrochlorothiazide Tablets